These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24332674)

  • 21. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction.
    Gallet R; Ternacle J; Damy T; Guendouz S; Bremont C; Seemann A; Gueret P; Dubois-Rande JL; Lim P
    Int J Cardiol; 2014 Sep; 176(2):450-5. PubMed ID: 25129291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U; Stöckl G; Werdan K
    Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
    Tendera M; Borer JS; Tardif JC
    Cardiology; 2009; 114(2):116-25. PubMed ID: 19468225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study.
    Tsutsui H; Momomura SI; Yamashina A; Shimokawa H; Kihara Y; Saito Y; Hagiwara N; Ito H; Yano M; Yamamoto K; Ako J; Inomata T; Sakata Y; Tanaka T; Kawasaki Y;
    Circ J; 2019 Sep; 83(10):2049-2060. PubMed ID: 31391387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
    Voors AA; van Veldhuisen DJ; Robertson M; Ford I; Borer JS; Böhm M; Komajda M; Swedberg K; Tavazzi L;
    Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
    Borer JS; Böhm M; Ford I; Komajda M; Tavazzi L; Sendon JL; Alings M; Lopez-de-Sa E; Swedberg K;
    Eur Heart J; 2012 Nov; 33(22):2813-20. PubMed ID: 22927555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Ford I;
    Eur J Heart Fail; 2013 Nov; 15(11):1296-303. PubMed ID: 23803951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
    Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
    Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
    Raja DC; Kapoor A; Sinha A; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel P
    Indian Heart J; 2018; 70(2):246-251. PubMed ID: 29716702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
    Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
    Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R; Cleland JG; Parsons S; Putzu P; Pellicori P; Dicken B; Boyalla V; Clark AL
    JACC Heart Fail; 2015 Mar; 3(3):224-30. PubMed ID: 25650369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.